CDKN2A Promoter Hypermethylation

CI-VAR-00003472Explore in graph →CIViC 27

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
CDKN2A Promoter Hypermethylation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID367 In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence and shorter overall survival. PMID 23111194 · Bradly et al., 2012 · Open in CIViC	civic
CDKN2A Promoter Hypermethylation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID368 In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence. PMID 23111194 · Bradly et al., 2012 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.